InVivo Therapeutics Names Investor Relations VP

Christopher McNulty has been appointed to an expanded role as vice president of investor relations and corporate communications at InVivo Therapeutics, in addition to his position as vice president of business development. Mr. McNulty will lead an integrated corporate communications effort for its strategic focus on developing therapies for spinal cord injury that will include investor relations, public relations, medical/scientific communications, patient advocacy, and the spinal cord injury (SCI) community. 
 
Mr. McNulty joins the company from Repligen Corp., where he served as senior director of business development, responsible for out-licensing programs for rare neurodegenerative diseases. Previously, he was director of corporate development at Seventh Sense Biosystems and associate director of business development and alliance management at Genzyme Corp.
 
Mark Perrin, InVivo’s chief executive officer, said, “Combining our investor relations, public relations, medical communications, and patient advocacy efforts into a comprehensive and synergistic corporate communications function will improve our communication efforts to all our constituents. We have engaged excellent partners with expertise in each of these areas to assist us in our efforts, and I look forward to our future activities.”